Ipsen’s ultra-rare bone disease drug flops in Phase II trial
Ipsen’s failure comes shortly after Regeneron’s FOP study met its endpoints, sparking an FDA approval submission.
22 December 2025
22 December 2025
Ipsen’s failure comes shortly after Regeneron’s FOP study met its endpoints, sparking an FDA approval submission.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.